PhaRMA

The big news stories last week featured clinical research, with some positive results and a disappointment. First up, Regeneron presented strong new data on Eylea that could open up a wider ophthalmic market for it and partner Bayer. Late-stage data on Heron Therapeutics' pain drug HTX-011 suggests it ...

With an ROE of 27.15%, Ajanta Pharma Limited (NSEI:AJANTPHARM) outpaced its own industry which delivered a less exciting 11.43% over the past year. Though, the impressiveness of AJANTPHARM's ROE is contingent on whether this industry-beating level can be sustained. A measure of sustainable ...

As the City of San Antonio considers whether to join a class action lawsuit against opioid manufacturers and distributors for their alleged role in a crisis that has been devastating locally, City officials must weigh the benefits and the costs of what can become lengthy, and costly, legal action. Pharmaceutical ...

Despite concerns that payers are clamping down on new drug launches, a dozen new meds are slated to reel in blockbuster sales in the coming years, according to a new report. In fact, Clarivate Analytics expects pharma to launch more blockbusters in 2018 than in any year in recent history. The analysts ...

ost Americans believe the pharmaceutical industry has too much influence in Washington and wields more clout in the nation's capital than Wall Street or the National Rifle Association, a new poll finds. Specifically, 72 percent say drug makers hold sway over Washington, compared with 69 percent who ...

Sun Pharma's $80 million psoriasis licensing deal with Merck & Co. just paid off with an FDA approval. But now, another challenge begins: The new med will go up against established psoriasis player Johnson & Johnson. The FDA has officially green-lighted the Indian drugmaker's Ilumya, an IL-23 inhibitor, ...

(KUTV) - Summit County filed a lawsuit against opioid drug manufacturers and opioid distributors Tuesday in Utah's Third Judicial District Court for Summit County. The lawsuit alleges the current nationwide opioid crisis was created "by misinformation, false claims, and marketing by the manufacturers and distributors of the ...

The role will position him on the other side of the negotiating table from his former employer and plenty of other pharma companies as a battle over drug pricing wages on. He's the second top Big Pharma ex to move into the payer world this month, following former GlaxoSmithKline CEO Andrew Witty, who's ...

“I almost got fired for defacing the corporate uniform ... Conformity was “not my strong suit.” -- Lisa Bair. Long before she founded and led companies, Lisa Bair sold fried chicken in brown polyester bell-bottom pants one summer after high school. She took the initiative to sew her way into an updated ...

Johnson & Johnson CFO Dominic Caruso is planning to retire in September. “Dominic made a big impact inside our company, and he is well-respected throughout our industry,” said CEO Alex Gorsky. He will be replaced by Joseph Wolk, VP of investor relations, who has worked at J&J for 19 years.

Biotech company Amgen has selected Omnicom Media Group agency Hearts & Science as its media agency of record, following a review launched in October and handled by Ark Advisors, Omnicom Media Group confirmed. Omnicom sister shop SSCG retained media duties for Amgen brands marketed to ...

As pharma products launch into increasingly competitive markets, branding becomes more important. And that's why FCB Health has launched BX: Brand Experience Design Group, its first stand-alone, full service branding agency focused on health and wellness. The newly independent agency will focus ...

GlaxoSmithKline commences late stage study with Benlysta (belimumab) and Roche's Rituxan (rituximab) in adult patients with systemic lupus erythematosus (SLE). Analysis focus: Arena Pharmaceuticals. Today we will discuss Arena Pharmaceuticals (NASDAQ:ARNA), which was up nearly 30% in ...

Miels - a long-time protege of AstraZeneca CEO Pascal Soriot, whose departure sparked a legal spat between the rival drugmakers - is a key lieutenant for Walmsley as she tries to overhaul the core pharma business. The unit has lagged rivals like Novartis and Merck in producing multibillion-dollar ...

The FDA is taking steps towards limiting the amount of nicotine allowed in cigarettes. The government agency said in an advanced notice that it is working towards a guideline “where nicotine levels in cigarettes do not spur or sustain addiction for some portion of potential smokers.” (CNBC).

The law firm of Baron & Budd will serve as a lead firm in a new lawsuit on behalf of Milwaukee County against many of the nation's largest pharmaceutical manufacturers and distributors for their role in creating a widespread diversion of prescription opiates for nonmedical purposes. The case was filed in ...

RALEIGH – More than 1,000 pharmaceutical manufacturing leaders gathered at the Raleigh Convention Center Tuesday focused on cutting-edge technologies designed to improve the delivery of drugs to patients with life-threatening illnesses. The 25th Annual Life Sciences and Technology Conference, ...

The biopharma industry faced plenty of uncertainty in 2017, but for most companies, the year delivered a rebound from stagnation, EP Vantage reports. Some rebounded far more than others—and some went the other direction. And there was one clear and overwhelming winner: AbbVie, which more than ...

"There is a growing body of research showing that the 340B program is driving up costs for patients and the health care system," said Stephen J. Ubl, President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA). "The biopharmaceutical industry has long supported the 340B ...

Analysts who follow the field say digital products are getting more direct attention from pharma CEOs who now see their development as a business imperative, as opposed to a supplemental service with marginal importance to their companies. “The CEOs are coming to us and saying, 'I have a strategic ...

China's enormous population, coupled with the rise of disease and illness, make the country a prime market for pharmaceutical companies, one in which U.S. and British pharma heavyweights are increasingly investing. Xi plans to improve the Chinese pharmaceutical industry to counter this reliance on ...